报价延迟最少15分钟:2026/05/23 06:44 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.48 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-6.76/-0.70
|
|
企业价值
4.07M
|
| 资产负债 |
|
每股账面净值
-1.80
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.01M
|
|
每股收益
0.08
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| 60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees. |
